One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study [PDF]
Therapeutic Advances in Hematology, 2020 Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase ...
Gerard Socié +2 more
exaly +4 more sources
Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab [PDF]
Kidney International ReportsIntroduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death.
Franz Schaefer +2 more
exaly +4 more sources
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study [PDF]
Annals of HematologyRavulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH.
Anna Paola Iori +35 more
doaj +3 more sources
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome [PDF]
Drugs, 2021 Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its terminal elimination half-life, resulting in a more ...
Yahiya Y. Syed (6594444)
core +4 more sources
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Neurology and Therapy, 2023 This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu +9 more
doaj +2 more sources
Kidney Medicine, 2023 Rationale and Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval.
Yan Wang +5 more
doaj +2 more sources
Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice [PDF]
Frontiers in NeurologyPurposeTo describe the early experience of ravulizumab use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG).MethodsThis multicenter retrospective study included AChR+ve gMG patients who were treated with ravulizumab
Nakul Katyal +4 more
doaj +2 more sources
Journal of Comparative Effectiveness Research, 2023 Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden.
Teri Mauch +2 more
exaly +2 more sources
Hematology Reports, 2023 Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman
exaly +3 more sources
Ravulizumab in neuromyelitis optica spectrum disorder: first clinical experience in Chile [PDF]
Frontiers in ImmunologyBackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a neuroimmunological astrocytopathy mediated by anti-aquaporin-4 (AQP4-IgG) antibodies that trigger complement-dependent cytotoxicity and activation of the terminal complement cascade in the ...
Tamara Santibáñez +9 more
doaj +2 more sources